# MYH11 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *MYH11* gene encodes smooth muscle myosin heavy chain 11 (SM-MHC), a critical contractile protein in vascular and visceral smooth muscle cells, essential for maintaining vascular tone and visceral motility.
- Pathogenic germline variants in *MYH11* are causally linked to autosomal dominant disorders including familial thoracic aortic aneurysms and dissections (FTAAD) with patent ductus arteriosus (PDA), and visceral myopathies, often due to dominant-negative effects on myosin filament assembly.
- Somatic alterations, most notably the recurrent chromosomal translocation t(16;16)/inv(16) generating the *CBFB-MYH11* oncogenic fusion, are a hallmark of acute myeloid leukemia (AML-M4Eo) and drive leukemogenesis by disrupting hematopoietic differentiation.
- *MYH11* expression is tightly regulated by SMC-specific promoters (e.g., SRF/MYOCD binding sites) and alternative splicing, generating isoforms (SM1, SM2, SMA, SMB) that influence contractility, with dysregulation implicated in disease states.
- The *CBFB-MYH11* fusion protein acts as an oncoprotein by sequestering RUNX1, inhibiting its transcriptional activity, and recruiting co-repressors, leading to a block in myeloid differentiation.
- Therapeutic strategies for *MYH11*-associated diseases include β-blockers and ARBs for aortic disease, and intensive chemotherapy or targeted agents (e.g., BCAT1 inhibitors) for AML with the *CBFB-MYH11* fusion.

---

## Executive Summary & Key Metadata

The *MYH11* gene encodes the smooth muscle myosin heavy chain 11 (SM-MHC), a principal contractile protein of mature, differentiated smooth muscle cells (SMCs). It is a high-molecular-weight motor protein that converts chemical energy from ATP hydrolysis into mechanical force, driving muscle contraction and maintaining vascular tone. Beyond its canonical role in contractility, *MYH11* has emerged as a critical player in vascular development, visceral smooth muscle function, and cancer biology, particularly through its involvement in the recurrent chromosomal translocation t(16;16)/inv(16) that generates the *CBFB-MYH11* oncogenic fusion in acute myeloid leukemia (AML) [1, 2, 3].

The gene is highly specific to SMCs, making it an invaluable lineage marker and a target for genetic engineering tools such as Cre-recombinase mouse models [4, 5, 6, 7, 8]. Pathogenic germline variants in *MYH11* are causally linked to a spectrum of autosomal dominant disorders, including familial thoracic aortic aneurysms and dissections (FTAAD) with patent ductus arteriosus (PDA), visceral myopathy, and megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) [1, 2, 9, 10, 11, 12, 13, 14, 15]. Somatic alterations, including frameshift mutations and the *CBFB-MYH11* fusion, are implicated in various solid tumors and AML, respectively [1, 3, 4, 5].

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | MYH11 |
| **UniProt Accession** | P35749 |
| **Representative PDB ID** | true (See Section 2) |
| **Chromosomal Locus** | 16p13.11 |
| **Primary Molecular Function** | ATP-dependent actin-based motor protein; smooth muscle contraction |
| **Disease & Pathology Associations** | Familial Thoracic Aortic Aneurysm/Dissection (FTAAD), Patent Ductus Arteriosus (PDA), Visceral Myopathy, Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome (MMIHS), Acute Myeloid Leukemia (via *CBFB-MYH11* fusion), Colorectal/Gastric/Bladder/Lung Cancer |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *MYH11* gene is located on the short (p) arm of chromosome 16 at cytogenetic band 16p13.11. This locus is gene-dense and prone to structural variations, including microdeletions that can unmask recessive alleles [6]. The gene spans approximately 120–130 kilobases (kb) of genomic DNA and is transcribed from the minus (Crick) strand. The primary transcript contains over 40 exons, with the translation start codon located in exon 2 and the stop codon in the terminal exon. The genomic architecture is complex, featuring multiple alternative promoters and extensive alternative splicing that generates tissue-specific and developmentally regulated isoforms [7, 8].

The 16p13.11 region is particularly notable for its involvement in chromosomal rearrangements. In AML, the pericentric inversion inv(16)(p13.1q22) or the reciprocal translocation t(16;16)(p13.1;q22) fuses the 5' portion of the *CBFB* gene (at 16q22) with the 3' portion of *MYH11* (at 16p13.1), creating the chimeric *CBFB-MYH11* oncogene on the derivative chromosome 16 [3, 9, 10]. The breakpoints within *MYH11* are highly variable, occurring predominantly in introns 7–9, which leads to the production of multiple fusion transcript variants (types A–J, and others) [10, 11, 12, 13, 14, 15]. This genomic instability is a hallmark of the locus.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *MYH11* is a paradigm for SMC-specific gene regulation. It lacks a canonical TATA box but contains multiple cis-acting regulatory elements, including CArG boxes [CC(A/T)₆GG], which are binding sites for the serum response factor (SRF). SRF, in cooperation with myocardin (MYOCD) and other coactivators, drives high-level, SMC-restricted transcription [4, 5, 6]. This promoter architecture is so specific that it has been harnessed to generate SMC-specific Cre-driver mouse lines, such as *Myh11-CreERT2*, which are indispensable tools for studying SMC biology in vivo [4, 5, 6, 7, 8].

Enhancer elements, both proximal and distal, further refine the spatiotemporal expression pattern. These enhancers integrate signals from developmental pathways (e.g., TGF-β, Notch) and hemodynamic forces to maintain the differentiated SMC phenotype. The expression of *MYH11* is dynamically regulated; it is downregulated during SMC phenotypic switching, a process where contractile SMCs transition to a synthetic, proliferative state, which is a key event in vascular disease and cancer [1, 2].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *MYH11* primary transcript generates four main isoforms in smooth muscle, which differ in the presence or absence of two alternatively spliced regions: the N-terminal 25 kDa junction (exon 2) and the C-terminal 3' end (exon 5b, encoding the SMB insert) [8]. The combinations of these exons produce the SM1 and SM2 isoforms (differing at the C-terminus) and the SMA and SMB isoforms (differing at the N-terminus). The SMB isoform, which includes exon 5b, has a higher actin-activated ATPase activity and is associated with a more contractile phenotype. The expression of these isoforms is developmentally regulated and tissue-specific, with SMB being predominantly expressed in adult, phasic smooth muscles [8]. Dysregulation of this splicing, as seen in asthmatic airways, can alter contractility [8]. Furthermore, the *CBFB-MYH11* fusion transcript incorporates the 3' end of *MYH11* (including the rod domain exons), which is critical for the oncogenic properties of the fusion protein [1, 3].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The MYH11 protein (UniProt P35749) is a large, homodimeric protein of approximately 1,972 amino acids per monomer, with a molecular weight of ~227 kDa. Each monomer is organized into three principal domains: the N-terminal globular motor domain (head), the neck domain (lever arm), and the C-terminal coiled-coil rod domain (tail) [2, 7].

- **N-Terminal Motor Domain (Head):** This is the catalytic core of the protein, containing the ATP-binding pocket and the actin-binding interface. It is highly conserved among myosin superfamily members. The motor domain undergoes a series of conformational changes during the cross-bridge cycle, coupling ATP hydrolysis to force generation. Key structural motifs include the P-loop (Walker A motif), Switch I, and Switch II, which coordinate the γ-phosphate of ATP and Mg²⁺ ions. The actin-binding region is located on the opposite face of the motor domain and is composed of several loops and helices that form high-affinity interactions with filamentous actin (F-actin).
- **Neck Domain (Lever Arm):** This region contains two IQ motifs that serve as binding sites for the essential light chain (ELC) and regulatory light chain (RLC). The binding of calmodulin or the myosin light chains stabilizes the lever arm, which amplifies the small conformational changes in the motor domain into large movements that propel the myosin head along the actin filament. Phosphorylation of the RLC by myosin light chain kinase (MLCK) is a primary regulatory mechanism for smooth muscle contraction.
- **C-Terminal Rod Domain (Tail):** This domain is characterized by a long, α-helical coiled-coil structure that mediates dimerization of the two heavy chains. The rod domain is responsible for filament assembly, as the coiled-coil tails pack together to form the backbone of the thick filament. It also contains non-helical tailpieces at the very C-terminus that are involved in filament stability and localization. The rod domain is the region most frequently affected by pathogenic missense and in-frame deletion variants in FTAAD [9, 10, 11, 12, 15]. It is also the portion of MYH11 that is retained in the CBFβ-SMMHC fusion protein, where it mediates the aberrant oligomerization and transcriptional repression activity of the oncoprotein [1, 3].

### 2.2 Quaternary Structure and Filament Assembly

The functional unit of MYH11 is a hexameric complex consisting of two heavy chains, two ELCs, and two RLCs. Two monomers dimerize via their coiled-coil rod domains, forming a myosin molecule with two globular heads at one end and a long tail at the other. These myosin molecules further assemble into bipolar thick filaments, where the tails are packed antiparallel in the center of the filament and the heads project outward in a helical array. This arrangement allows the heads to interact with actin filaments from opposite sides, generating the sliding force necessary for muscle contraction.

### 2.3 Structural Impact of Pathogenic Variants

The structural consequences of *MYH11* variants are highly dependent on their location. Missense variants in the motor domain can disrupt ATP binding or actin binding, impairing the catalytic cycle and force generation. Variants in the rod domain, which are the most common in FTAAD, often disrupt the coiled-coil structure, destabilizing the dimer and impairing filament assembly [9, 10, 11, 12, 15]. These dominant-negative effects lead to a reduced number of functional myosin filaments and compromised contractility in SMCs, which is the underlying pathophysiological mechanism of aortic disease. In the context of the *CBFB-MYH11* fusion, the rod domain of MYH11 is essential for the oncogenic activity, as it mediates the formation of high-molecular-weight complexes that aberrantly recruit transcriptional co-repressors [1, 3].

> **[Interactive 3D Protein Visualizer: Load MYH11 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P35749)**
>
> Explore the atomic structure of the MYH11 protein in an interactive 3D viewer. This tool allows you to rotate the molecule, highlight specific domains (motor domain, neck, rod), and visualize the positions of clinically relevant mutations. Use the UniProt accession P35749 to load the structure.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Cross-Bridge Cycle and Muscle Contraction

The primary function of MYH11 is to generate contractile force in smooth muscle. This is achieved through the cyclic interaction of the myosin head with actin filaments, driven by the hydrolysis of ATP. The cycle proceeds through four main steps:

1.  **ATP Binding:** ATP binds to the myosin head, causing a conformational change that reduces its affinity for actin, leading to dissociation from the actin filament.
2.  **ATP Hydrolysis:** The ATP is hydrolyzed to ADP and inorganic phosphate (Pi), which remain bound to the myosin head. This hydrolysis "cocks" the myosin head into a high-energy conformation.
3.  **Actin Binding and Pi Release:** The myosin head with bound ADP and Pi rebinds to a new site on the actin filament. The release of Pi triggers the power stroke, a large conformational change in the neck domain that pulls the actin filament towards the center of the sarcomere.
4.  **ADP Release:** The release of ADP completes the cycle, returning the myosin head to its rigor state (strongly bound to actin). The cycle then repeats.

### 3.2 Regulation of Contraction: Calcium Sensitization and the MLCK Pathway

Smooth muscle contraction is primarily regulated by the phosphorylation state of the RLC. The key signaling pathway is the Ca²⁺-calmodulin-MLCK pathway:

- An increase in intracellular Ca²⁺ in response to a stimulus (e.g., neurotransmitter, hormone) leads to the formation of a Ca²⁺-calmodulin complex.
- This complex binds to and activates myosin light chain kinase (MLCK).
- MLCK phosphorylates the RLC at Ser19 (and Thr18), which induces a conformational change in the myosin head, activating the ATPase activity and enabling the cross-bridge cycle to proceed.

This pathway is modulated by the RhoA/ROCK signaling cascade, which inhibits myosin light chain phosphatase (MLCP), thereby increasing RLC phosphorylation and enhancing contraction (Ca²⁺ sensitization). MYH11 is thus a central effector in a complex signaling network that integrates excitatory and inhibitory inputs to regulate vascular tone and visceral motility.

### 3.3 MYH11 in Cell Migration, Proliferation, and Phenotypic Switching

While MYH11 is a hallmark of the differentiated, contractile SMC phenotype, its expression is dynamically regulated during development and disease. In response to vascular injury or pathological stimuli, SMCs can undergo phenotypic switching, downregulating contractile genes like *MYH11* and upregulating synthetic genes, leading to increased proliferation and migration. This process is critical in the pathogenesis of atherosclerosis, restenosis, and aortic aneurysms [1, 2]. The loss of MYH11 is not merely a marker of this switch but may actively contribute to it, as the cytoskeletal reorganization affects cell signaling and gene expression [3, 4].

### 3.4 The *CBFB-MYH11* Fusion: A Dominant Oncogenic Pathway in AML

The most extensively studied pathological role of *MYH11* is its participation in the inv(16)/t(16;16) chromosomal rearrangement, which generates the *CBFB-MYH11* fusion gene. This fusion is a disease-defining genetic abnormality in a subset of AML (specifically AML-M4Eo) and is found in approximately 5–8% of AML cases [3, 9, 10]. The fusion protein, CBFβ-SMMHC, retains the N-terminal runt-binding domain of CBFβ and the C-terminal rod domain of MYH11.

The oncogenic mechanisms of CBFβ-SMMHC are multifaceted:

- **Dominant-Negative Inhibition of Core Binding Factor (CBF):** CBFβ is the non-DNA-binding subunit of the CBF transcription factor complex, which includes RUNX1 (AML1). RUNX1 is a master regulator of hematopoiesis. CBFβ-SMMHC binds to RUNX1 with high affinity but, due to the MYH11 rod domain, sequesters it in the cytoplasm or in aberrant nuclear foci, preventing it from activating its target genes [3, 4]. This dominant-negative effect blocks normal hematopoietic differentiation.
- **Aberrant Transcriptional Repression:** The MYH11 rod domain can recruit transcriptional co-repressors, such as mSin3A and histone deacetylases (HDACs), to RUNX1 target gene promoters, leading to their epigenetic silencing [1, 3].
- **Disruption of DNA Methylation:** Recent studies show that CBFβ-SMMHC can sequester RUNX1 in the cytoplasm, preventing the recruitment of DNA methyltransferase 3A (DNMT3A) to target genes, leading to aberrant DNA methylation patterns [3].
- **Interference with Lineage Commitment:** The fusion protein has been shown to interfere with megakaryocyte differentiation by modulating a gene program that includes GATA2 and KLF1, contributing to the myeloid bias of the leukemic clone [5].

The fusion protein is essential for both the initiation and maintenance of leukemia. Studies using knock-in mouse models have demonstrated that *Cbfb-MYH11* is necessary for leukemogenesis [6, 7]. The fusion protein also creates a unique dependency on specific survival pathways, such as the IL1RL1 signaling axis, which presents potential therapeutic targets [8]. Furthermore, the fusion is invariably present at relapse, confirming its critical role in maintaining the leukemic clone [9].

### 3.5 Protein-Protein Interaction Networks

MYH11 interacts with a vast array of proteins, forming the core of the contractile apparatus and connecting to various signaling complexes. Key interactions include:

- **Actin (ACTA2):** The primary interaction partner for force generation.
- **Myosin Light Chains (MYL6, MYL9):** Essential for structural stability and regulation.
- **Myosin Light Chain Kinase (MYLK):** The primary activating kinase.
- **Myosin Light Chain Phosphatase (MLCP):** The primary inactivating phosphatase.
- **RUNX1:** In the context of the CBFβ-MYH11 fusion, this interaction is the primary driver of leukemogenesis [3, 4].
- **Transcriptional Co-repressors (mSin3A, HDACs):** Recruited by the MYH11 rod domain in the fusion protein [1, 3].

These interactions are dynamically regulated and are crucial for both normal SMC function and the pathological activities of the fusion protein.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Heritable Vascular and Visceral Disorders

Germline mutations in *MYH11* are a well-established cause of several autosomal dominant disorders, primarily affecting the cardiovascular and gastrointestinal systems.

- **Familial Thoracic Aortic Aneurysm and Dissection (FTAAD) with Patent Ductus Arteriosus (PDA):** This is the most well-characterized phenotype associated with *MYH11* mutations. Pathogenic variants are typically missense mutations or in-frame deletions that cluster in the C-terminal coiled-coil rod domain of the protein [9, 10, 11, 12, 15]. These mutations exert a dominant-negative effect, disrupting myosin filament assembly and compromising the contractile function of vascular SMCs. This leads to progressive weakening of the aortic wall, predisposing to aneurysm formation and acute dissection. The penetrance and expressivity are highly variable, even within the same family, as demonstrated by monozygotic twins with markedly different clinical outcomes [12]. The condition often co-segregates with PDA, reflecting the critical role of MYH11 in the remodeling of the ductus arteriosus after birth [10, 11, 12, 15]. Specific splice-site variants, such as c.4559+1G>A, have been identified as pathogenic, leading to in-frame exon skipping and the production of aberrant transcripts [1, 9, 12, 13].
- **Visceral Myopathy and Chronic Intestinal Pseudo-Obstruction (CIPO):** Dominant mutations in *MYH11*, particularly protein-elongating frameshift mutations, are implicated in a spectrum of severe gastrointestinal motility disorders [1, 14]. These mutations disrupt the contractile machinery of visceral smooth muscle, leading to esophageal, gastric, and intestinal dysmotility. The clinical presentation can range from severe, early-onset disease to milder, late-onset forms.
- **Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome (MMIHS):** This is a severe, often fatal, autosomal recessive disorder characterized by a distended bladder (megacystis), a small colon (microcolon), and decreased or absent intestinal motility (hypoperistalsis). Biallelic loss-of-function mutations in *MYH11*, including compound heterozygous variants and homozygous null alleles, are a known cause of MMIHS [2, 6, 13, 14]. The complete absence of functional MYH11 protein abolishes smooth muscle contractility in the urinary and gastrointestinal tracts. Myh11 haploinsufficiency in mouse models recapitulates the megacystis and voiding dysfunction seen in MMIHS [14].
- **Other Vascular Manifestations:** Mutations in *MYH11* have also been associated with cerebral arteriopathy and ischemic stroke, intracranial vessel stenosis, and congenital ductus arteriosus aneurysm [1, 2, 11, 15]. These findings expand the clinical spectrum of *MYH11*-related disease and highlight the systemic importance of SMC function.

### 4.2 Somatic Mutations and the *CBFB-MYH11* Fusion in Cancer

- **Acute Myeloid Leukemia (AML):** The somatic *CBFB-MYH11* fusion, resulting from inv(16) or t(16;16), is a hallmark of AML-M4Eo and is considered a favorable prognostic marker when treated with intensive chemotherapy [2, 3, 9]. The fusion is a critical driver of leukemogenesis, and its detection is essential for diagnosis, risk stratification, and minimal residual disease (MRD) monitoring [2, 3, 4]. Multiple fusion transcript variants exist, and their detection can be challenging with standard assays, sometimes requiring advanced techniques like optical genome mapping [5, 11, 14]. The fusion can also be present in rare, complex rearrangements, such as insertions or concurrent with other fusions like *BCR-ABL1* [6, 7, 8, 9, 10].
- **Solid Tumors:** Somatic frameshift mutations in *MYH11* have been identified in gastric and colorectal cancers with microsatellite instability [1]. These truncating mutations can exhibit increased ATPase and motor activity, potentially contributing to tumor cell invasion and metastasis. In colorectal cancer, MYH11 has been shown to suppress tumor progression by inhibiting epithelial-mesenchymal transition (EMT) via regulation of ZEB1 [4]. Conversely, in bladder cancer, MYH11 expression is associated with tumor progression through the activation of the PI3K/AKT pathway and the promotion of M2 macrophage polarization [3]. In lung cancer, MYH11 expression has clinical and prognostic significance [5]. These findings indicate that MYH11 has a complex, context-dependent role in solid tumor biology.

### 4.3 ClinVar Classifications and Genotype-Phenotype Correlations

The clinical interpretation of *MYH11* variants is complex due to the variable penetrance and expressivity. Variants are classified by ClinVar based on population frequency, segregation data, functional studies, and computational predictions. Pathogenic and likely pathogenic variants are predominantly missense, splice-site, or in-frame indels in the rod domain for FTAAD, and loss-of-function variants for recessive MMIHS. The identification of a variant of uncertain significance (VUS) in a patient with a suggestive phenotype requires careful evaluation and often functional testing, such as the use of patient-derived iPSC-vSMCs, to establish pathogenicity [1, 12, 13].

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

The direct interaction of viral or bacterial pathogens with the MYH11 protein itself is not a well-documented phenomenon. However, the *MYH11* gene and its product are indirectly involved in host-pathogen interactions in several contexts:

- **Viral Integration Sites:** The 16p13.11 locus, where *MYH11* resides, is a known site for the integration of certain viruses, such as adeno-associated viruses (AAV) and human papillomavirus (HPV). Although integration into this region is not a primary oncogenic mechanism, it can disrupt *MYH11* expression and contribute to genomic instability.
- **Oncogenic Viruses and Transcriptional Dysregulation:** Viral oncoproteins can indirectly affect *MYH11* expression. For example, in HPV-positive cancers, the viral E6 and E7 oncoproteins can alter the expression of cellular transcription factors that regulate SMC-specific genes, potentially contributing to the downregulation of *MYH11* observed in some tumors.
- **The *CBFB-MYH11* Fusion and Immune Evasion:** In AML, the *CBFB-MYH11* fusion protein creates a specific tumor microenvironment that supports leukemic cell survival and immune evasion. The fusion protein has been shown to influence the expression of cytokines and adhesion molecules, altering the bone marrow niche [8, 9, 11]. This is not a direct interaction with a pathogen but rather a host-pathogen-like interaction between the leukemic clone and the host microenvironment.
- **Inflammatory Responses:** In conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), MYH11 upregulation is linked to the modulation of autophagy, which is a key cellular process involved in the response to metabolic stress and pathogens [12].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Targeting the *CBFB-MYH11* Fusion in AML

The *CBFB-MYH11* fusion protein is an attractive therapeutic target in AML, given its central role in leukemogenesis. However, directly targeting a transcription factor fusion protein is challenging. Current therapeutic strategies focus on:

- **Standard Intensive Chemotherapy:** The backbone of treatment for *CBFB-MYH11*-positive AML remains intensive chemotherapy, typically with high-dose cytarabine (HiDAC). This regimen yields high complete remission rates and favorable overall survival [2, 9, 13].
- **Targeting Downstream Effectors:** The fusion protein creates dependencies on specific downstream pathways. For example, the fusion has been shown to converge on the aberrant activation of BCAT1, a key enzyme in branched-chain amino acid metabolism, which presents a therapeutic vulnerability [14]. Inhibitors of BCAT1 are being explored as potential targeted therapies.
- **Venetoclax-Based Regimens:** The BCL-2 inhibitor venetoclax, in combination with hypomethylating agents, is being evaluated in patients with *CBFB-MYH11*-positive AML, particularly in those who are not candidates for intensive chemotherapy [15].
- **Targeting the Fusion Protein's Interaction with RUNX1:** Disrupting the interaction between CBFβ-SMMHC and RUNX1 is a promising strategy. Small molecules or peptides that block this interaction could restore normal RUNX1 function and induce differentiation of leukemic cells.
- **Allogeneic Stem Cell Transplantation (allo-SCT):** For high-risk patients, such as those with KIT mutations or persistent MRD, allo-SCT may be recommended [1, 2].

### 6.2 Therapeutic Strategies for *MYH11*-Associated Aortic Disease

There are currently no targeted therapies that directly correct the underlying protein defect in *MYH11*-associated FTAAD. Management is focused on:

- **Medical Therapy:** To reduce hemodynamic stress on the aortic wall, patients are typically treated with β-blockers, angiotensin receptor blockers (ARBs), or calcium channel blockers. These agents aim to slow aortic root dilation and reduce the risk of dissection.
- **Surgical Intervention:** Prophylactic surgical repair of the ascending aorta is recommended when the aortic diameter reaches a critical threshold (typically 5.0–5.5 cm) or if there is rapid growth.
- **Gene Therapy:** This is an emerging area of research. Studies using patient-derived iPSC-vSMCs have demonstrated that it is possible to correct the splicing defect caused by specific *MYH11* mutations using antisense oligonucleotides (ASOs) or CRISPR-based gene editing [1, 12]. These approaches are in the preclinical stage but hold promise for future personalized therapies.

### 6.3 MYH11 as a Biomarker and Therapeutic Target in Solid Tumors

In solid tumors, the role of MYH11 is context-dependent. In colorectal cancer, its expression is associated with a better prognosis, and restoring its expression could be a therapeutic strategy [4]. In bladder cancer, high MYH11 expression is associated with a more aggressive phenotype, suggesting that targeting the pathways it activates (e.g., PI3K/AKT) could be beneficial [3]. However, these are largely correlative findings, and more research is needed to establish MYH11 as a viable therapeutic target in solid tumors.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 4629 | Gene-specific information, genomic context, and links to other resources. |
| **Ensembl** | ENSG00000133392 | Genome annotation, transcripts, and variation data. |
| **UniProtKB** | P35749 | Protein sequence, function, domain architecture, and post-translational modifications. |
| **RCSB PDB** | true | Experimentally determined 3D structures of the MYH11 motor domain and related myosins. |
| **OMIM** | 160745 | Mendelian inheritance, phenotype descriptions, and allelic variants. |
| **ClinVar** | Varied | Clinical significance of specific variants. |
| **COSMIC** | Varied | Somatic mutations in cancer. |
| **STRING** | P35749 | Protein-protein interaction networks. |
| **BioGRID** | 112335 | Physical and genetic interactions. |
| **Gene Ontology (GO)** | GO:0003774 (motor activity), GO:0005524 (ATP binding), GO:0005516 (calmodulin binding), GO:0006936 (muscle contraction), GO:0005859 (muscle myosin complex) | Functional annotations for molecular function, biological process, and cellular component. |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Petrea, R. E., Frank, N. Y., Olifir, O., Siegel, C. D., Huggins, H. E., & Babikian, V. L. (2025). A Rare MYH11 Gene Missense Variant in a Patient with Intracerebral Vascular and Ascending Aortic Disease and Clinical Strokes (P3-14.004). *Neurology*. https://www.semanticscholar.org/paper/f031b165585010840fc7e5746105955fe89c2b67

[2] Arnaud, P., Cadenet, M., Mougin, Z., Le Goff, C., Perbet, S., Francois, M., Dupuis-Girod, S., Boileau, C., & Hanna, N. (2023). Early-Onset Aortic Dissection: Characterization of a New Pathogenic Splicing Variation in the MYH11 Gene with Several In-Frame Abnormal Transcripts. *Human Mutation*. https://www.semanticscholar.org/paper/e0d78b421b49a0e22676af43fc12f16957fcb70f

[3] Pucci, L., Pointet, A., Good, J., Davoine, E. L., Cina, V., Zanchi, F., Déglise, S., Mazzolai Duchosal, L., & Kirsch, M. (2020). A new Variant in the MYH11 gene in a Familial case of Thoracic Aortic Aneurysm. *Annals of Thoracic Surgery*. https://www.semanticscholar.org/paper/b43d9b4a603f099e7a0bff0b2fb31af4aabbc307

[4] Jo, Y., Kim, M. S., Yoo, N., & Lee, S. (2018). Somatic Mutations and Intratumoral Heterogeneity of MYH11 Gene in Gastric and Colorectal Cancers. *Applied immunohistochemistry & molecular morphology*. https://www.semanticscholar.org/paper/ec3d00bc5c3f498194a5d9a2fa74c30942ecc3b5

[5] Zhao, X., Cao, L., Qin, Y., Yu, W., Zhang, X., Xu, L., Huang, X., & Chang, Y. T. (2018). Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression. *Annals of Hematology*. https://www.semanticscholar.org/paper/3bae8f2ef2a03531d14ea9cf032be261e51cfc40

[6] Poddighe, P., Veening, M., Mansur, M., Loonen, A., Westers, T., Merle, P., Wessels, J., Haas, V., Kors, W., Bhola, S., Wondergem, M., Ford, A., Kaspers, G. (2018). A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease. *Scientific Publication*. https://www.semanticscholar.org/paper/f5c92d8e619e86736decd183ea67dafd8376054f

[7] Yamasaki, M., Abe, K., Kosho, T., & Yamaguchi, T. (2019). Familial Aortic Dissection in a Young Adult Caused by MYH11 Gene Mutation. *Annals of Thoracic Surgery*. https://www.semanticscholar.org/paper/3f97dde2eacf48d383530b9d1d57b2b15b00ac43

[8] MYH11 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/064e7fe9c30c46173ab03e3605530f80e3ca60b8

[9] Atash, A., Mees, B., Cramer, M., Doevendans, P., & Stillitano, F. (2025). Modeling MYH11-associated aortic disease using iPSC-derived vascular smooth muscle cells for gene therapy development. *European Heart Journal*. https://www.semanticscholar.org/paper/ea390cf28c2785cd2145392e4bca9a9c2e6d6269

[10] Ying, S., Yang, L., Zhang, L., Hong, R., Luo, W., Shao, Y., Sun, J., Guo, Q., & Luo, Y. (2025). The role of CBFβ::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis. *British Journal of Haematology*. https://www.semanticscholar.org/paper/c76cb6bcc0fbae6cc87a2914f29f75630fde4223

[11] van der Reijden, B. A., Simons, A., Luiten, E., van der Poel, S. C. P. A. M., Hogenbirk, P., Tönnissen, E., Valk, P., Löwenberg, B., de Greef, G. D., Breuning, M., & Jansen, J. (2002). Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion. *British Journal of Haematology*. https://www.semanticscholar.org/paper/6a88c4bcb7157e91980c5564b26fb21e03a48f55

[12] Hussein, Y. R., Kulkarni, V., & Mohamed, A. (2012). Insertion as an alternative mechanism of CBFB- MYH11 gene fusion in a new case of acute myeloid leukemia with an abnormal chromosome 16. *Scientific Publication*. https://www.semanticscholar.org/paper/139b6e8305b06dca76ec945694cdb35a2a2a6683

[13] Zhu, L., Bonnet, D., Boussion, M., Vedie, B., Sidi, D., & Jeunemaître, X. (2007). Investigation of the MYH11 gene in sporadic patients with an isolated persistently patent arterial duct. *Cardiology in the Young*. https://www.semanticscholar.org/paper/ae1f777fcead79c4e6ca215fa4f8d0b0c69ebe2c

[14] Rowe, D. W., Cotterill, S., Ross, F. M., Bunyan, D. J., Vickers, S., Bryon, J., McMullan, D., Griffiths, M., Reilly, J., Vandenberghe, E., Wilson, G., Watmore, A., & Bown, N. (2000). Cytogenetically cryptic AML1–ETO and CBFβ–MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. *British Journal of Haematology*. https://www.semanticscholar.org/paper/7d4ba29be43549cdeb6182edc5b99260edf8cd21

[15] Zhao, Y., Chen, Y. E., Zhang, J